People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ImmusanT, Inc. | — | Biotechnology | Series B | $32.7M | $788.8M | 2014 |
| Arisaph Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2013 |
Kevin Ferro at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Ferro on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Koestler | 2 | 2 |
| Steven Gillis | 1 | 23 |
| Thomas Daniel | 1 | 4 |
| Claude Benedict | 1 | 2 |
| Sundar Kodiyalam | 1 | 2 |
| Joseph Suarez | 1 | 1 |
| Antonio Gotto | 1 | 1 |
| Rex Roten | 1 | 1 |
| Michael Jaharis | 1 | 1 |
| Craig Estwick | 1 | 1 |
| Justin Sun | 1 | 1 |
| Leslie Williams | 1 | 1 |
| William Bachovchin | 1 | 1 |
| Ceclia Gonzalo | 1 | 1 |
| Madias Nicolaos | 1 | 1 |
| Steven Jaharis | 1 | 1 |
| Robert Baldini | 1 | 1 |
| Christopher Kiritsy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.